Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 10 | 2022 | 530 | 3.550 |
Why?
|
| Thrombolytic Therapy | 4 | 2022 | 127 | 1.430 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 139 | 1.430 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2020 | 124 | 1.390 |
Why?
|
| Brain Ischemia | 5 | 2022 | 175 | 1.270 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 98 | 1.150 |
Why?
|
| Thrombectomy | 2 | 2020 | 69 | 0.900 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 179 | 0.870 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 188 | 0.850 |
Why?
|
| Pandemics | 5 | 2020 | 588 | 0.830 |
Why?
|
| Intracranial Thrombosis | 1 | 2020 | 22 | 0.760 |
Why?
|
| Health Services Misuse | 1 | 2020 | 15 | 0.740 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 70 | 0.720 |
Why?
|
| Conflict of Interest | 1 | 2020 | 25 | 0.710 |
Why?
|
| Patient Transfer | 1 | 2020 | 101 | 0.700 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 103 | 0.690 |
Why?
|
| Fabry Disease | 1 | 2019 | 9 | 0.680 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2019 | 19 | 0.680 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 61 | 0.660 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 546 | 0.650 |
Why?
|
| Cardiology | 1 | 2020 | 107 | 0.640 |
Why?
|
| Leukoaraiosis | 1 | 2015 | 1 | 0.540 |
Why?
|
| Recovery of Function | 2 | 2019 | 220 | 0.530 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2014 | 70 | 0.430 |
Why?
|
| Hospitalization | 4 | 2021 | 714 | 0.430 |
Why?
|
| Telemedicine | 1 | 2019 | 461 | 0.430 |
Why?
|
| Heart Arrest | 1 | 2014 | 161 | 0.410 |
Why?
|
| Humans | 23 | 2022 | 54581 | 0.390 |
Why?
|
| Aged | 10 | 2021 | 10043 | 0.380 |
Why?
|
| Triage | 2 | 2021 | 73 | 0.370 |
Why?
|
| Autoimmune Diseases | 2 | 2020 | 114 | 0.350 |
Why?
|
| Retrospective Studies | 6 | 2020 | 6520 | 0.340 |
Why?
|
| Endovascular Procedures | 2 | 2022 | 191 | 0.340 |
Why?
|
| Middle Aged | 10 | 2021 | 13036 | 0.340 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 247 | 0.330 |
Why?
|
| Male | 13 | 2021 | 27656 | 0.300 |
Why?
|
| Female | 13 | 2021 | 28520 | 0.290 |
Why?
|
| United States | 5 | 2020 | 5292 | 0.280 |
Why?
|
| Arkansas | 4 | 2019 | 2172 | 0.270 |
Why?
|
| Time Factors | 4 | 2020 | 3223 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 1240 | 0.230 |
Why?
|
| Treatment Outcome | 5 | 2022 | 5594 | 0.220 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 2359 | 0.210 |
Why?
|
| Cavernous Sinus | 1 | 2022 | 16 | 0.200 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2022 | 13 | 0.200 |
Why?
|
| Critical Care | 2 | 2021 | 223 | 0.200 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 19 | 0.190 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 17 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 97 | 0.190 |
Why?
|
| Neuromuscular Diseases | 1 | 2020 | 31 | 0.190 |
Why?
|
| Iodine Compounds | 1 | 2020 | 7 | 0.180 |
Why?
|
| Health Care Sector | 1 | 2020 | 17 | 0.180 |
Why?
|
| Multiple Sclerosis | 1 | 2020 | 73 | 0.180 |
Why?
|
| Databases, Factual | 2 | 2020 | 697 | 0.180 |
Why?
|
| Brain Edema | 1 | 2020 | 39 | 0.180 |
Why?
|
| Drug Industry | 1 | 2020 | 40 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2022 | 1545 | 0.180 |
Why?
|
| Administration, Oral | 1 | 2020 | 471 | 0.170 |
Why?
|
| alpha-Galactosidase | 1 | 2019 | 9 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 137 | 0.170 |
Why?
|
| Hospitals | 1 | 2020 | 189 | 0.170 |
Why?
|
| Fluorocarbons | 1 | 2019 | 53 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2020 | 220 | 0.170 |
Why?
|
| Prevalence | 3 | 2020 | 1044 | 0.160 |
Why?
|
| Contrast Media | 1 | 2020 | 216 | 0.160 |
Why?
|
| Medicare | 1 | 2020 | 253 | 0.160 |
Why?
|
| Coronary Angiography | 1 | 2020 | 367 | 0.160 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 132 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 136 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2019 | 304 | 0.140 |
Why?
|
| Physicians | 1 | 2020 | 254 | 0.140 |
Why?
|
| Adult | 5 | 2020 | 14239 | 0.140 |
Why?
|
| Plasminogen Activators | 1 | 2015 | 4 | 0.130 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 233 | 0.130 |
Why?
|
| Forensic Pathology | 1 | 2014 | 9 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2020 | 2534 | 0.120 |
Why?
|
| Autopsy | 1 | 2014 | 52 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2015 | 639 | 0.120 |
Why?
|
| Malaria, Falciparum | 1 | 2013 | 12 | 0.120 |
Why?
|
| Optic Neuritis | 1 | 2013 | 21 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1058 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3420 | 0.100 |
Why?
|
| Health Behavior | 1 | 2014 | 274 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 638 | 0.100 |
Why?
|
| Risk Factors | 2 | 2019 | 3915 | 0.090 |
Why?
|
| Intubation, Intratracheal | 2 | 2021 | 126 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1609 | 0.080 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 43 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 107 | 0.050 |
Why?
|
| Headache | 1 | 2022 | 79 | 0.050 |
Why?
|
| Cranial Sinuses | 1 | 2021 | 11 | 0.050 |
Why?
|
| Arthritis, Psoriatic | 1 | 2020 | 9 | 0.050 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2020 | 11 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 97 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 53 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2020 | 88 | 0.050 |
Why?
|
| Mortality | 1 | 2020 | 107 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2020 | 81 | 0.040 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2020 | 46 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 117 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 553 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2020 | 90 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2020 | 98 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 82 | 0.040 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 67 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 74 | 0.040 |
Why?
|
| Drug-Eluting Stents | 1 | 2020 | 108 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 104 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2021 | 214 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 405 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2019 | 235 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 679 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 743 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1154 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 411 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2020 | 324 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 1360 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1708 | 0.030 |
Why?
|
| Antimalarials | 1 | 2013 | 29 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 3903 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2020 | 4220 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6941 | 0.020 |
Why?
|
| Child | 1 | 2020 | 7483 | 0.020 |
Why?
|